Blast crisis (BC) is the major remaining challenge in the management of chronic myeloid leukemia (CML). It is now generally accepted that BC is the consequence of continued BCR-ABL activity leading to genetic instability, DNA damage and impaired DNA repair. Most patients with BC carry multiple mutations, and up to 80% show additional chromosomal aberrations in a non-random pattern. Treatment with tyrosine kinase inhibitors (TKI) has improved survival in BC modestly, but most long term survivors are those who have been 
Introduction
Blast crisis (BC) is the major remaining challenge in the management of chronic myeloid leukemia (CML). The introduction of an inhibitor targeted at the BCR-ABL tyrosine kinase (imatinib) has fundamentally changed treatment of CML.
1 BCR-ABL expression can be reduced by imatinib to very low or non-detectable levels in the majority of patients. 2 Median survival in chronic phase (CP) is estimated at a median of 25 to 30 years. Progress to advanced phase CML or BC has been reduced to 1 -1.5% per year 1 as compared to more than 20% per year in the pre-imatinib era. 3 Prevalence of CML is estimated to increase by a factor of about 10 within the next 40 years. 4 Once BC has appeared, however, the prognosis of imatinib treated patients is not much better than that after conventional therapy. 5 Median survival after diagnosis of BC currently ranges between 7 and 11 months as compared to 3 to 4 months in the pre-imatinib era. Very few long term survivors after diagnosis of BC have been reported. Most of these represent recipients of transplants during a second CP. The therapeutic dilemma of BC has recently been well summarized. 6 More research is needed to fully understand the mechanisms underlying progression to BC. It is distressing that in CML BC a true malignancy evolves under our eyes. The two current burning questions in CML are:
How can we best manage patients who progress to BC in spite of appropriate treatment? How can we best prevent BC?
How I define and diagnose BC
First attempts at the definition of BC date back more than forty years. 7 The generally used definition which underlies virtually all current clinical CML trials and the European LeukemiaNet (ELN) management recommendations rests on at least 30% blasts in blood or marrow or the demonstration of extramedullary blastic infiltrates. 8 The more recent WHO definition proposes a blast count of 20% in analogy to the definition of acute myeloid
For personal use only. on October 24, 2017. by guest www.bloodjournal.org From leukemia (AML) 9 . Both definitions are not supported by biological evidence. A new definition would regroup approximately 10% of patients. 10 Patients with 20 to 29% blasts have significantly better prognoses than patients with more than 30% blasts. Since most clinicians and trialists would likely use the definition based upon their own data and experience I suggest awaiting the results of clinical and biological research for a new evidence-based definition of BC.
To diagnose BC, I do complete blood and differential counts and a bone marrow analysis with cytogenetics ( Table 1) . Cytogenetic evolution is the most consistent predictor of blast transformation. Flow cytometry or cytochemistry are needed to determine the type of BC (myeloid or lymphoid). Molecular genetics with mutation analysis are needed to choose the appropriate tyrosine kinase inhibitor (TKI). Consensus recommendations when to perform mutation analyses have been published on behalf of the ELN. 11 A donor search for allo-SCT should be started immediately.
What are the clinical and laboratory features observed in BC? Do they play a role in prognostic prediction?
Clinically BC may present with night sweats, weight loss, fever, bone pain or symptoms of
anemia. An increased risk of infections and of bleeding is also observed. The common laboratory features include high WBC and blast counts, decreased hemoglobin values and platelet numbers and, in up to 80% of BC patients, additional cytogenetic aberrations (ACA) in addition to the Philadelphia (Ph)-chromosome. Most frequent are the so called "major route" ACA (trisomy 8, additional Ph-chromosome, isochromosome (17q), trisomy 19) which are non-random and considered relevant for the pathogenesis of BC. [12] [13] [14] Less frequent are the so called "minor route" cytogenetic aberrations involving chromosome 3 aberrations, loss of the Y-chromosome and other rarer aberrations. Minor route ACA are less likely involved in
For personal use only. on October 24, 2017. by guest www.bloodjournal.org From BC-pathogenesis and may mainly indicate genetic instability. The impact of major route ACA at diagnosis on progression and survival has been shown. 15 A variety of mutations has been associated with progression to BC. Mutations of the BCR-ABL tyrosine kinase domain have been observed in up to 80% of patients. 11 Several features have been associated with an unfavorable prognosis such as clonal evolution, more than 50% blast cells, high platelet counts, short duration of the CP and extramedullary disease. [26] [27] [28] Although non-random, chromosomal individuality of each clonal evolution is a characteristic feature of BC similar to other cancers, which has been compared with speciation in evolution. 29, 30 The most important predictor of a poor prognosis is an unsatisfactory response to initial therapy.
What is the rationale for treating BC?
Treatment of BC is guided by our understanding of BC pathogenesis. Good in depth reviews on the biology of BC have been published. [31] [32] [33] According to current evidence BC is the direct consequence of continued BCR-ABL activity 31 , possibly via oxidative stress and reactive oxygen species (ROS) 34, 35 , causing DNA damage and impaired DNA repair 36 ( Figure 1 ) and, in a vicious circle, genomic instability by more mutations, gene doublings, translocations and chromosomal breakage. 37 The latter effect of BCR-ABL would explain what is observed during clonal evolution and progression to BC. BCR-ABL has been shown to produce ROS in hemopoietic cells.
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This consideration underlies the therapeutic principle in CML to hit "hard and early" in order to reduce the BCR-ABL positive cell pool as early and as deep as possible and to thereby achieve the best possible outcome. 39 The validity of this principle may be limited by quiescent CD34 positive CML cells which evade currently available pharmacotherapy 40 or by a speculative preexisting genetic instability responsible for the generation of BCR-ABL. This is confirmed by experience of the German CML Study Group (Fig. 2) . The cumulative incidence of BC, as a consequence of more effective treatment early on, has decreased from close to 70% after 8 years 25 years ago to currently about 5% in CML Study IV under an optimized dose of imatinib.
42

Management of BC -what we have learned from the pre-imatinib era
In the late 1960s / early 1970s attempts were made to treat BC with treatment protocols designed for acute leukemia (AL). It was observed that 30% of the patients responded to a Dasatinib: Three studies on 400 BC-patients pretreated with imatinib including 119 with lymphoid BC showed hematologic remission rates of 33%-61% (lymphoid BC 36%-80%), major cytogenetic remission (MCR) rates of 35%-56%, a one year survival of 42%-50%, a two year survival of 20%-30% and a median survival of 8-11 months.
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The largest of the studies, a randomized open label phase 3 study on 214 patients with 61
in lymphoid BC tried to optimize the dose-schedule of dasatinib, stratified for lymphoid and myeloid BC, and compared dasatinib at 140 mg once daily with 70 mg twice daily.
The study yielded similar efficacy and improved tolerability for the once daily regimen.
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Pleural effusion which is observed in up to one third of dasatinib treated BC patients may necessitate dose reduction, diuretics and, in some cases, corticosteroids. In summary, survival after BC is better after treatment with TKI than after conventional therapies, but with a median survival of less than one year, outcome is still unsatisfactory.
The modest survival progress that is achieved by TKI after BC is illustrated by the experience of the German CML Study Group in Fig. 3 . Median survival has increased from 4 months in the pre-imatinib era (n=699) to 9 months under imatinib (n=65).
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When I recommend allogeneic stem cell transplantation (allo-SCT)
If a return to CP or a complete remission has been achieved, I proceed to allo-SCT as quickly as possible, if the patient can tolerate the procedure and has a donor. The search for a donor should be instituted as early as possible. The best outcome continues to be observed in patients after transplantation, although allo-SCT is successful in only a minority of BC patients mostly after prior return to a second CP. In an overview of the European Group for Blood and Marrow Transplantation from 1980 -2003 two year survival rates are 16%-22%. 61 Most patients were transplanted in the pre-imatinib era. In a recent report from the German CML Study Group, 3 year survival of 28 imatinib pretreated patients transplanted in advanced phases (25 in BC) was 59%. 62 The data show convincingly that allo-SCT represents the best chance of long term remission or cure in BC. Current experience recommends allo-SCT in primary BC after an attempt has been made with a suitable TKI selected according to mutation profile in combination with chemotherapy as needed to achieve a second CP. In lymphoid BC, dasatinib should be combined with vincristine and prednisone.
In BC after imatinib failure a 2nd generation TKI (according to mutation profile) has to be weighed against other options such as AL-type therapy (also in combination with TKI) to give the best chance of a return to CP or cytoreduction. If patients carry the T315I mutation, this has to be considered in choosing the appropriate regimen (investigational agents such as ponatinib, AL-type therapy) followed by allo-SCT. 63 Transplantation should be performed with a HLA identical related or matched unrelated donor and an EBMT-score 0-4. 64 Standard conditioning with busulfan and cyclophosphamide (BuCy) or total body irradiation (TBI)
should be used. Reduced intensity conditioning is not recommended in this situation outside studies. Sudden onset BC under imatinib is a rare event, but full disease eradication by allo-SCT may be successful 65 and is warranted. Post-transplantation maintenance with TKI appears reasonable. Maintenance with dasatinib is recommended in lymphoid BC for neuroprophylaxis as it is known to cross the blood brain barrier. 57 Monitoring of BCR-ABL transcript levels should be done at regular intervals (3 months initially, 6 months later on, if transcripts are not detectable or stable).
As a consequence of these recommendations more CML patients are now transplanted in second chronic or advanced phases than in first CP. 66 Most long term survivors shown in Fig. 3 represent transplant recipients (72%).
What is the promise of new investigational approaches?
A number of investigational approaches are under exploration. A selection is shown in Table   3 . Some agents are in clinical trial and can be tried after conventional treatments (TKI and AL-type therapy) have failed. Some approaches may be suitable for BC prevention.
Imatinib in combination:
Several small studies have focused on the combination of imatinib at 600 mg -800 mg with chemotherapy or other agents. In a phase 1/2 trial on 16 BC-patients imatinib 600mg daily was combined with mitoxantrone/etoposide. 67 Hematologic response rate was 81% with a one year survival of about 50% including 6 patients after allo-SCT.
Another study combined imatinib 600 mg with decitabine in 10 patients and reported a median survival of 15 weeks. 68 The combination of imatinib 600 mg with low dose ara-C and idarubicin in 19 patients with myeloid BC showed hematologic remissions in 47%. Median survival was 5 months. 69 In a phase 1 study with the combination of the farnesyltransferase inhibitor lonafarnib with imatinib 2 out of 3 BC patients showed hematologic improvement. 70 A study on 12 patients combining imatinib and homoharringtonine after priming with G-CSF reported hematologic or cytogenetic response in all patients. 71 None of these studies has provided convincing evidence that the combinations are superior to imatinib alone. None of these approaches is likely to provide a breakthrough in the near future, since due to the numerous blastic genotypes and their instability no single therapeutic approach can soon be expected to be successful in all patients.
Can BC be prevented? Is early prediction possible?
The low progression rates of CML under TKI indicate that BC can be prevented (see Fig. 2 ).
Also, it is well known that very low or undetectable BCR-ABL transcripts after allo-SCT correlate with low relapse rates. 96 For (table 4) . Also BMI1 and CIP2A levels at diagnosis have been reported predictive of BC. 74, 104 Another indicator of progression risk is clonal evolution i.e. the acquisition of ACA in the course of the disease. [105] [106] [107] [108] The relevance of clonal evolution has not changed in the imatinib era. [109] [110] [111] [112] Mutations may be associated with clonal evolution. 113 The pattern of chromosome abnormalities is not altered by TKI treatment. 114 The prognostic impact of ACA may depend on the type of ACA. 112 Some ACA types (major route, complex karyotypes) appear to imply poorer prognosis than others that may only indicate genetic instability. 115 Acquired ACA are high risk features by ELN definition and indicate treatment failure if they appear under therapy. 8 The prognostic relevance of rare clonal evolution in Ph-negative cells (observed in less than 5% of cases) remains uncertain. [116] [117] [118] [119] The evolution of gene expression profiles may also allow to diagnose disease progression.
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Early response indicators are the probably best predictors of progression.. 8, 121 These include cytogenetic and molecular responses determined by monitoring all patients. Failure to achieve defined landmarks will detect high risk patients as early as 3 months after diagnosis. (Table 3) .
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Conclusion -how I manage CML-BC
The algorithm in Fig. 4 gives an overview on how I approach management of a patient with In view of the limited therapeutic options once BC has been diagnosed the best management of BC is probably its prevention by a rigorous and early reduction to low levels, or elimination of BCR-ABL. Regular molecular monitoring is required ( 
